指南与共识妇科产科

降低风险输卵管卵巢切除术与自然绝经前激素替代治疗:科学影响论文第66号

Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
指南 / 共识 · BJOG · 2021-10-20

本文讨论高风险绝经前女性因预防卵巢癌行输卵管卵巢切除术后早绝经的激素替代治疗(HRT)管理。BRCA1/2等基因变异及强家族史增加卵巢癌风险,预防性手术最有效但导致早绝经及相关症状。HRT通常建议用于51岁前早绝经且无乳腺癌史者,有子宫者需雌激素联合孕激素,无子宫者单用雌激素;早绝经女性HRT不增加乳腺癌风险,包括BRCA携带者。

要点

  • 预防性输卵管卵巢切除术后早绝经女性,51岁前通常建议HRT以降低早绝经健康风险。
  • 有子宫者HRT需雌激素联合孕激素以保护子宫内膜,无子宫者单用雌激素。
  • 早绝经女性HRT不增加乳腺癌风险,包括BRCA1/2携带者预防性手术后。

核心结论

  • 预防性输卵管卵巢切除术后早绝经女性通常建议HRT至平均绝经年龄51岁,以最小化早绝经相关健康风险。
  • 早绝经女性HRT不增加乳腺癌风险,包括BRCA1/2携带者预防性手术后。

研究设计与样本

  • BJOG科学影响论文,基于现有证据综述高风险绝经前女性预防性输卵管卵巢切除术后HRT使用。

主要发现

  • 切除卵巢导致早绝经,引起潮热、出汗、情绪变化、骨密度下降、记忆问题、心脏病风险增加及性欲或性功能受损。
  • HRT通常建议用于51岁前早绝经且无乳腺癌史女性;有子宫者需雌激素联合孕激素,无子宫者单用雌激素。
  • 早绝经女性HRT不增加乳腺癌风险,包括BRCA1/2携带者预防性手术后。
  • 雌激素受体阳性乳腺癌史者通常不提供HRT;受体阴性乳腺癌史者由妇科医生与肿瘤医生个案决定HRT安全性。
  • 无法使用HRT者可选择行为疗法和非激素药物,但效果不如HRT;同时建议规律运动、健康生活方式和避免症状诱因。

关键数值与推荐

  • HRT通常建议用于51岁前(英国女性平均绝经年龄)早绝经且无乳腺癌史女性。
  • 有子宫者HRT应包括雌激素联合孕激素以预防子宫内膜增生;无子宫者单用雌激素。
  • 雌激素受体阳性乳腺癌史者通常不提供HRT;受体阴性乳腺癌史者个案决定。

临床怎么用

  • 预防性手术后早绝经女性应评估HRT适应证,51岁前通常建议使用以降低早绝经健康风险。
  • 根据子宫是否存在选择雌激素联合孕激素或单用雌激素方案。
  • 有乳腺癌史者需与肿瘤医生协作,受体阳性者通常不用HRT,受体阴性者个案评估。
  • 无法使用HRT者可考虑行为疗法和非激素药物,但需告知效果较差。
  • 术前应充分咨询预防性手术和HRT的利弊,帮助女性做出知情决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This paper deals with the use of hormone replacement therapy (HRT) after the removal of fallopian tubes and ovaries to prevent ovarian cancer in premenopausal high risk women. Some women have an alteration in their genetic code, which makes them more likely to develop ovarian cancer. Two well-known genes which can carry an alteration are the BRCA1 and BRCA2 genes. Examples of other genes associated with an increased risk of ovarian cancer include RAD51C, RAD51D, BRIP1, PALB2 and Lynch syndrome genes. Women with a strong family history of ovarian cancer and/or breast cancer, may also be at increased risk of developing ovarian cancer. Women at increased risk can choose to have an operation to remove the fallopian tubes and ovaries, which is the most effective way to prevent ovarian cancer. This is done after a woman has completed her family. However, removal of ovaries causes early menopause and leads to hot flushes, sweats, mood changes and bone thinning. It can also cause memory problems and increases the risk of heart disease. It may reduce libido or impair sexual function. Guidance on how to care for women following preventative surgery who are experiencing early menopause is needed. HRT is usually advisable for women up to 51 years of age (average age of menopause for women in the UK) who are undergoing early menopause and have not had breast cancer, to minimise the health risks linked to early menopause. For women with a womb, HRT should include estrogen coupled with progestogen to protect against thickening of the lining of the womb (called endometrial hyperplasia). For women without a womb, only estrogen is given. Research suggests that, unlike in older women, HRT for women in early menopause does not increase breast cancer risk, including in those who are BRCA1 and BRCA2 carriers and have preventative surgery. For women with a history of receptor-negative breast cancer, the gynaecologist will liaise with an oncology doctor on a case-by-case basis to help to decide if HRT is safe to use. Women with a history of estrogen receptor-positive breast cancer are not normally offered HRT. A range of other therapies can be used if a woman is unable to take HRT. These include behavioural therapy and non-hormonal medicines. However, these are less effective than HRT. Regular exercise, healthy lifestyle and avoiding symptom triggers are also advised. Whether to undergo surgery to reduce risk or not and its timing can be a complex decision-making process. Women need to be carefully counselled on the pros and cons of both preventative surgery and HRT use so they can make informed decisions and choices.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Manchanda R, Gaba F, Talaulikar V, et al. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66. BJOG. 2021. PMID: 34672090. doi:10.1111/1471-0528.16896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。